Jayamas Medica Industri
PT Jayamas Medica Industri Tbk manufactures and sells medical devices in Indonesia, the United States of America, and South America. The company operates through three segments: Manufacturing, Distribution, and Retail. It offers medical disposables and consumables comprising medical gloves, syringes, masks, gauze, bandages, urine bag, foley catheter, alcoholic tissue, etc.; antiseptic and disinfe… Read more
Jayamas Medica Industri (OMED) - Net Assets
Latest net assets as of September 2025: Rp2.64 Trillion IDR
Based on the latest financial reports, Jayamas Medica Industri (OMED) has net assets worth Rp2.64 Trillion IDR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp3.03 Trillion) and total liabilities (Rp390.05 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp2.64 Trillion |
| % of Total Assets | 87.15% |
| Annual Growth Rate | 30.4% |
| 5-Year Change | 162.55% |
| 10-Year Change | N/A |
| Growth Volatility | 21.41 |
Jayamas Medica Industri - Net Assets Trend (2019–2024)
This chart illustrates how Jayamas Medica Industri's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jayamas Medica Industri (2019–2024)
The table below shows the annual net assets of Jayamas Medica Industri from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp2.50 Trillion | +11.15% |
| 2023-12-31 | Rp2.25 Trillion | +8.50% |
| 2022-12-31 | Rp2.07 Trillion | +66.16% |
| 2021-12-31 | Rp1.25 Trillion | +31.02% |
| 2020-12-31 | Rp950.57 Billion | +43.68% |
| 2019-12-31 | Rp661.59 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jayamas Medica Industri's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 124.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rp1.58 Trillion | 64.15% |
| Common Stock | Rp676.47 Billion | 27.48% |
| Other Comprehensive Income | Rp-17.34 Billion | -0.70% |
| Other Components | Rp223.19 Billion | 9.07% |
| Total Equity | Rp2.46 Trillion | 100.00% |
Jayamas Medica Industri Competitors by Market Cap
The table below lists competitors of Jayamas Medica Industri ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alembic Limited
NSE:ALEMBICLTD
|
$62.26 Million |
|
Indústrias Romi S.A
SA:ROMI3
|
$62.27 Million |
|
Eolus Vind AB (publ)
ST:EOLU-B
|
$62.27 Million |
|
FingerMotion Inc
NASDAQ:FNGR
|
$62.29 Million |
|
Sun Max Tech Ltd
TW:6591
|
$62.24 Million |
|
Adagene Inc
NASDAQ:ADAG
|
$62.23 Million |
|
THN Corporation
KO:019180
|
$62.21 Million |
|
ARTHA RESOURCES
F:16T
|
$62.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jayamas Medica Industri's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,218,219,114,000 to 2,461,336,347,000, a change of 243,117,233,000 (11.0%).
- Net income of 321,673,462,000 contributed positively to equity growth.
- Dividend payments of 77,929,488,000 reduced retained earnings.
- Other comprehensive income decreased equity by 626,742,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp321.67 Billion | +13.07% |
| Dividends Paid | Rp77.93 Billion | -3.17% |
| Other Comprehensive Income | Rp-626.74 Million | -0.03% |
| Other Changes | Rp1.00K | +0.0% |
| Total Change | Rp- | 10.96% |
Book Value vs Market Value Analysis
This analysis compares Jayamas Medica Industri's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.79x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 12.24x to 2.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | Rp20.75 | Rp254.00 | x |
| 2020-12-31 | Rp34.70 | Rp254.00 | x |
| 2021-12-31 | Rp45.25 | Rp254.00 | x |
| 2022-12-31 | Rp75.55 | Rp254.00 | x |
| 2023-12-31 | Rp81.98 | Rp254.00 | x |
| 2024-12-31 | Rp90.96 | Rp254.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jayamas Medica Industri utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.07%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.06%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.15x
- Recent ROE (13.07%) is below the historical average (33.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 40.29% | 18.42% | 1.85x | 1.18x | Rp170.07 Billion |
| 2020 | 73.01% | 34.37% | 1.41x | 1.51x | Rp591.62 Billion |
| 2021 | 45.96% | 25.27% | 1.29x | 1.41x | Rp440.25 Billion |
| 2022 | 13.98% | 16.43% | 0.69x | 1.23x | Rp81.35 Billion |
| 2023 | 11.69% | 14.93% | 0.67x | 1.16x | Rp37.54 Billion |
| 2024 | 13.07% | 17.06% | 0.67x | 1.15x | Rp75.54 Billion |
Industry Comparison
This section compares Jayamas Medica Industri's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $112,336,061,985
- Average return on equity (ROE) among peers: 53.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jayamas Medica Industri (OMED) | Rp2.64 Trillion | 40.29% | 0.15x | $62.25 Million |
| Mark Dynamics Indonesia Tbk PT (MARK) | $237.74 Billion | 34.45% | 0.34x | $36.64 Million |
| PT Hetzer Medical Indonesia Tb (MEDS) | $32.46 Billion | 82.03% | 0.54x | $2.39 Million |
| SURI (SURI) | $66.81 Billion | 43.14% | 2.31x | $39.35 |